News | January 11, 2010

Hypertension Drug With Less-Frequent Dosing May Gain Market Share

January 11, 2010 – A hypertension drug using a combination of telmisartan/amlodipine, which requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan), may earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, the agent would earn comparable patient share of 25 percent according to surveyed European cardiologists.

These patient shares are significantly higher than Diovan/Tareg's current patient share (6.1 percent) and are higher than the patient share achieved by any current hypertension drug. The survey was conducted by Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

"In the crowded hypertension market, 25 to 30 percent patient shares are unlikely reached without any evidence of long-term clinical benefit,” said Decision Resources Therapeutic Area Director Nikhil Mehta, M.Eng. “However, the magnitude of these estimates indicate cardiologists' concern about patient compliance to therapy and their desire for a novel drug that requires less-frequent dosing than Diovan/Tareg, as long as this agent has similar cardio-protective effects as Diovan/Tareg."

The new report, entitled “Hypertension: Among Fixed-Dose Combination Agents, AIIRA/CCBs Stand Out for Their Superior Efficacy and Safety,” also finds that the fixed-dose combination telmisartan/amlodipine will earn Decision Resources' proprietary clinical gold standard status for hypertension in 2013 and through 2018 following its approval for the disease. Telmisartan/amlodipine has competitive advantages over other emerging therapies because it combines an effective angiotensin II receptor antagonist (AIIRA) – telmisartan – with a calcium-channel blocker (CCB) – amlodipine. Decision Resources said the combination of an AIIRA and a CCB provides superior efficacy and safety compared with other fixed-dose combinations.

"We expect telmisartan/amlodipine to remain the clinical gold standard through 2018 because there are no other emerging agents expected to launch during this time that will have a clinical profile superior to this AIIRA/CCB combination," Mehta said.

For more information: www.decisionresources.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Overlay Init